Daniel Loeb
Third Point
Daniel Loeb FOLEY TRASIMENE ACQUISITI-A stake
total: 588
Third Point BFT trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q1
According to 2026 Q2 report, Daniel Loeb doesn't hold any FOLEY TRASIMENE ACQUISITI-A (BFT) shares. To date, the estimated cost basis is nearly $15.1 for "buy" trades and estimated average "sell" price is $15.1. Third Point first purchased BFT in 2020 Q4, initially acquiring about 5.00M shares. Since the initial investment in FOLEY TRASIMENE ACQUISITI-A (BFT), Third Point has made 1 more transaction.
When did Daniel Loeb sell FOLEY TRASIMENE ACQUISITI-A (BFT)?
Daniel Loeb sold off the entire FOLEY TRASIMENE ACQUISITI-A (BFT) position in 2021 Q1.
When did Daniel Loeb buy FOLEY TRASIMENE ACQUISITI-A (BFT)?
Daniel Loeb first invested in FOLEY TRASIMENE ACQUISITI-A (BFT) in 2020 Q4 at the reported quarter-end price of $15.10 per share.
What's the cost basis of Third Point's BFT stake?
The estimated cost basis for FOLEY TRASIMENE ACQUISITI-A (BFT) stake is around $15.10 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $15.10
- Weighted AVG sell price:
- $15.10
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.